Carolinas Wealth Consulting’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-36
Closed -$2.61K 294
2025
Q1
$2.61K Hold
36
﹤0.01% 744
2024
Q4
$2.67K Sell
36
-92
-72% -$6.44K ﹤0.01% 768
2024
Q3
$8.45K Sell
128
-782
-86% -$56.8K ﹤0.01% 589
2024
Q2
$84.1K Buy
910
+33
+4% +$2.92K 0.02% 286
2024
Q1
$83.8K Buy
877
+735
+518% +$61.7K 0.02% 296
2023
Q4
$10.8K Hold
142
﹤0.01% 530
2023
Q3
$9.05K Sell
142
-25
-15% -$2.01K ﹤0.01% 533
2023
Q2
$15.8K Buy
167
+62
+59% +$5.39K ﹤0.01% 518
2023
Q1
$8.69K Hold
105
﹤0.01% 628
2022
Q4
$7.83K Buy
105
+36
+52% +$2.77K ﹤0.01% 648
2022
Q3
$6K Buy
69
+25
+57% +$2.41K ﹤0.01% 642
2022
Q2
$4K Sell
44
-24
-35% -$2.48K ﹤0.01% 675
2022
Q1
$8K Hold
68
﹤0.01% 637
2021
Q4
$9K Sell
68
-393
-85% -$45.8K ﹤0.01% 625
2021
Q3
$52K Sell
461
-263
-36% -$30K 0.01% 338
2021
Q2
$75K Buy
724
+94
+15% +$8.86K 0.02% 304
2021
Q1
$53K Buy
630
+562
+826% +$47.5K 0.01% 350
2020
Q4
$6K Hold
68
﹤0.01% 631
2020
Q3
$5K Buy
68
+47
+224% +$3.67K ﹤0.01% 560
2020
Q2
$1K Buy
+21
New +$1.49K ﹤0.01% 564

Other funds holding EW

Carolinas Wealth Consulting's EW Position: Q2 2025 in Review

Carolinas Wealth Consulting sold out of Edwards Lifesciences (EW) in Q2 2025, closing a stake of 36 shares — an estimated $2.61K sold.

Carolinas Wealth Consulting first reported a position in EW in Q2 2020 and held it in 20 quarters. The position peaked at $84.1K in Q2 2024. 1,259 funds tracked by Wall St. Rank hold EW as of Q2 2025.

  • Carolinas Wealth Consulting reported no remaining Edwards Lifesciences position as of Q2 2025 after selling out during the quarter.
  • Carolinas Wealth Consulting sold 36 Edwards Lifesciences shares in Q2 2025, an estimated $2.61K.
  • Carolinas Wealth Consulting first reported a position in Edwards Lifesciences in Q2 2020 and held it in 20 quarters.
  • Carolinas Wealth Consulting's Edwards Lifesciences position peaked at $84.1K in Q2 2024.
  • 1,259 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2025.

Based on Carolinas Wealth Consulting's 13F filing for Q2 2025.